Can Trastuzumab Be Effective Against Tumors With Low HER2/Neu (ErbB2) Receptors?
- 10 August 2006
- journal article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (23) , 3722-3725
- https://doi.org/10.1200/jco.2006.06.5268
Abstract
No abstract availableThis publication has 38 references indexed in Scilit:
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Activation of ErbB2 by Overexpression or by Transmembrane Neuregulin Results in Differential Signaling and Sensitivity to HerceptinCancer Research, 2005
- Relationship of Epidermal Growth Factor Receptor Expression to ErbB-2 Signaling Activity and Prognosis in Breast Cancer PatientsJournal of Clinical Oncology, 2005
- TGFα expression impairs Trastuzumab-induced HER2 downregulationOncogene, 2005
- Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complexCancer Cell, 2004
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003
- ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingThe EMBO Journal, 1997
- c‐erbB‐3 protein expression in human breast cancer: comparison with other tumour variables and survivalHistopathology, 1994
- c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma—an immunocytochemical studyEuropean Journal Of Cancer, 1994
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989